Therapeutic potential of IL-10 and its viral homologues: an update

Bibliography

• FIORENTINO DF, BOND MW, MOSMANN TR: Two types of mouse T helper cell. IV. TH2 clones secrete a factor that inhibits cytokine production by TH1 clones. I Exp. Med. (1989) 170:2081–2095.
   Google Scholar
• MOORE KW, DE WAAL MALEFYT R, COFFMAN RL, O'GARRA A: Interleukin-10 and the interleukin-10 receptor. Ann. Rev Immunol (2001) 19:683–765.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of the biology of IL-10and its receptor.
   Google Scholar
• ASADULLAH K, STERRY W, VOLK HD: Interleukin-10 therapy — review of a new approach. Pharmacol Rev (2003) 55:241–269.
   PubMed Web of Science ®Google Scholar
• ••Excellent review focusing on the clinicalevaluation of IL-10.
   Google Scholar
• REDPATH S, GHAZAL P, GASCOIGNE NR: Hijacking and exploitation of IL-10 by intracellular pathogens. Trends Microbial. (2001) 9:86–92.
   PubMed Web of Science ®Google Scholar
• GROUX H: Type 1 T-regulatory cells: their role in the control of immune responses. Transplantation (2003) 75:8S–12S.
   Google Scholar
• •Review of the biology of Trl cells and their therapeutic potential.
   Google Scholar
• RONCAROLO MG, BATTAGLIA M, GREGORI S: The role of interleukin-10 in the control of autoimmunity.j. Autoimmun. (2003) 20:269–272.
   PubMed Web of Science ®Google Scholar
• •Review of the role of IL-10 in the generation and function of Trl cells as pertaining to the regulation of autoimrnunity.
   Google Scholar
• KOTENKO SV: The family of IL-10-related cytokines and their receptors: related, but to what extent? Cytokine Growth Factor Rev (2002) 13:223–240.
   PubMed Web of Science ®Google Scholar
• JOSEPHSON K, LOGSDON NJ, WALTER MR: Crystal structure of the IL-10/IL-10R1 complex reveals a shared receptor binding site. Immunity (2001) 15:35–46.
   PubMed Web of Science ®Google Scholar
• •Shows that IL-10R2 binds to the same site as IL-10R1 on the IL-10 dimer.
   Google Scholar
• HANADA T, YOSHIMURA A: Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev. (2002) 13:413–421.
   PubMed Web of Science ®Google Scholar
• BONDESON J, BROWNE KA, BRENNAN FM, FOXWELL BM, FELDMANN M: Selective regulation of cytokine induction by adenoviral gene transfer of IxBa into human macrophages: lipopolysaccharide-induced, but not zymosan-induced, proinflammatory cytokines are inhibited, but IL-10 is nuclear factor-KB independent. J. Immunol (1999) 162:2939–2945.
   PubMed Web of Science ®Google Scholar
• BOUWMAN P, PHILIPSEN S: Regulation of the activity of Spl-related transcription factors. MM. Cell. Endocrinol (2002) 195:27–38.
   PubMed Web of Science ®Google Scholar
• BRIGHTBILL HD, PLEVY SE, MODLIN RL, SMALE S: A prominent role for Spl during lipopolysaccharide-mediated induction of the IL-10 promoter in macrophages. Immunol (2000) 164: 1940-1951.
   Google Scholar
• MAW, LIM W, GEE K et al: The p38 mitogen-activated kinase pathway regulates the human interleukin-10 promoter via the activation of Spl transcription factor in lipopolysaccharide-stimulated human macrophages. J. Biol. Chem. (2001) 276:13664–13674.
   PubMed Web of Science ®Google Scholar
• ••Evidence that IL-10 induction by LPSinvolves Spl and the p38 MAPK.
   Google Scholar
• LIU YW, TSENG HP, CHEN LC, CHEN BK, CHANG WC: Functional cooperation of simian virus 40 promoter factor 1 and CCAAT/enhancer-binding protein 13 and 8 in lipopolysaccharide-induced gene activation of IL-10 in mouse macrophages. Immunol. (2003) 171:821–828.
   Web of Science ®Google Scholar
• FOEY AD, PARRY SL, WILLIAMS LM et al.: Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-a: role of the p38 and p42/44 mitogen-activated protein kinases. .1. Immunol. (1998) 160:920–928.
   Google Scholar
• BRANGER J, VAN DEN BLINK B, WEIJER S et al.: Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. .1. Immunol. (2002) 168:4070–4077.
   Google Scholar
• GUO X, GERL RE, SCHRADER JW: Defining the involvement of p38a MAP kinase in the production of anti-and pro-inflammatory cytokines using an SB-203580-resistant form of the kinase. Biol. Chem. (2003) 278:22237–22242.
   Web of Science ®Google Scholar
• ZAHALKA MA, BARAK V, TRAUB L, MOROZ C: PLIF induces IL-10 production in monocytes: a calmodulin-p38 mitogen-activated protein kinase-dependent pathway. FASEB (2003) 17:955–957.
   PubMed Web of Science ®Google Scholar
• BENKHART EM, SIEDLAR M, WEDEL A, WERNER T, ZIEGLER-HEITBROCK HW: Role of Stat3 in lipopolysaccharide-induced IL-10 gene expression. Immunol. (2000) 165:1612–1617.
   Web of Science ®Google Scholar
• •Evidence that Stat3 is involved in IL-10 induction by LPS.
   Google Scholar
• OKUGAWA S, OTA Y, KITAZAWA T et al.: Janus kinase 2 is involved in lipopolysaccharide-induced activation of macrophages. Am. I Physiol. Cell Physiol. (2003) 285:C399–C408.
   Web of Science ®Google Scholar
• ZIEGLER-HEITBROCK L, LOTZERICH M, SCHAEFER A et al.: IFN-a induces the human IL-10 gene by recruiting both IFN regulatory factor 1 and Stat3. .1 Immunol. (2003) 171:285–290.
   Google Scholar
• YI AK, YOON JG, YEO SJ et al: Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated TH1 response. I Immunol. (2002) 168:4711–4720.
   PubMed Web of Science ®Google Scholar
• HIRSCHFELD M, WEIS JJ, TOSHCHAKOV V et al: Signaling by Toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infect. Inman. (2001) 69:1477–1482.
   PubMed Web of Science ®Google Scholar
• •First evidence that certain TLR2 ligands preferentially induce IL-10 production in macrophages.
   Google Scholar
• SING A, ROST D, TVARDOVSKAIA N et al.: Yersinia V-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression. Exp. Med. (2002) 196:1017–1024.
   PubMed Web of Science ®Google Scholar
• MARTIN M, SCHIFFERLE RE, CUESTA N et al: Role of the phosphatidylinositol 3 kinase-Akt pathway in the regulation of IL-10 and IL-12 by Porphyromonas gingivalislipopolysaccharide. Immunol. (2003) 171:717–725.
   Web of Science ®Google Scholar
• MUN HS, AOSAI F, NOROSE K et al.: TLR2 as an essential molecule for protective immunity against Toxoplasma gondiiinfection. hat. Inman& (2003)15:1081–1087.
   Web of Science ®Google Scholar
• RIESE U, BRENNER S, DOCKE WD et al.: Catecholamines induce IL-10 release in patients suffering from acute myocardial infarction by transactivating its promoter in monocytic but not in T cells. Mol. Biochem. (2000) 212:45–50.
   Google Scholar
• BRENNER S, PROSCH S, SCHENKE-LAYLAND K et al.: cAMP-induced interleukin- 10 promoter activation depends on CCAAT/enhancer-binding protein expression and monocytic differentiation. J. Biol. Chem. (2003) 278:5597–5604.
   PubMed Web of Science ®Google Scholar
• ••Evidence that IL-10 gene transcription inmonocytes is regulated by CREB proteins.
   Google Scholar
• SHINOMIYA S, NARABA H, UENO A et al.: Regulation of TNFa and interleukin-10 production by prostaglandins I(2) and E(2): studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists. Biochem. Pharmacol. (2001) 61:1153–1160.
   PubMed Web of Science ®Google Scholar
• PACKARD KA, KHAN MM: Effects of histamine on TH1/TH2 cytokine balance. Int. Immunopharmacol. (2003) 3:909–920.
   PubMed Web of Science ®Google Scholar
• WILKIN F, STORDEUR P, GOLDMAN M, BOEYNAEMS JM, ROBAYE B: Extracellular adenine nucleotides modulate cytokine production by human monocyte-derived dendritic cells: dual effect on IL-12 and stimulation of IL-10. Lid. Immunol. (2002) 32:2409–2417.
   Web of Science ®Google Scholar
• SONG Z, BARVE S, CHEN T et al: ..Cadenosylmethionine (AdoMet) modulates endotwdn stimulated interleukin-10 production in monocytes. Am. I Physiol. Castrointest. Liver Physiol. (2003) 284:G949–G955.
   Web of Science ®Google Scholar
• REIS E SOUSA C, DIEBOLD SD, EDWARDS AD et al.: Regulation of dendritic cell function by microbial stimuli. Foam]. Biol. (2003) 51:67–68.
   Google Scholar
• VAN DER KLEIJ D, LATZ E, BROUWERS JF et al.: A novel host-parasite lipid cross-talk. Schistosomal lyso-phosphatidylserine activates toll-like receptor 2 and affects immune polarization. Biol. Chem. (2002) 277:48122–48129.
   Google Scholar
• QI H, DENNING TL, SOONG L: Differential induction of interleukin-10 and interleukin-12 in dendritic cells by microbial toll-like receptor activators and skewing of T-cell cytokine profiles. Infect. Immun. (2003) 71:3337–3342.
   PubMed Web of Science ®Google Scholar
• •Evidence that certain TLR2 ligands preferentially induce IL-10 production in DCs.
   Google Scholar
• FONTANA S, MORATTO D, MANGAL S et al.: Functional defects of dendritic cells in CD40-deficient patients. Blood (2003). [Electronically published ahead of print.]
   Google Scholar
• HARIZI H, JUZAN M, MOREAU JF, GUALDE N: Prostaglandins inhibit 5-lipoxygenase-activating protein expression and leukotriene B4 production from dendritic cells via an IL-10-dependent mechanism. I Immunol. (2003) 170:139–146.
   PubMed Web of Science ®Google Scholar
• PANTHER E, CORINTI S, IDZKO M et al.: Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood (2003) 101:3985–3990.
   PubMed Web of Science ®Google Scholar
• LAVELLE EC, MCNEELA E, ARMSTRONG ME et al.: Cholera toxin promotes the induction of regulatory T cells specific for bystander antigens by modulating dendritic cell activation. Immunol. (2003) 171:2384–2392.
   Web of Science ®Google Scholar
• MORITA R, UKYO N, FURUYA M, UCHIYAMA T, HORI T: Atrial natriuretic peptide polarizes human dendritic cells toward a T2-promoting phenotype through its receptor guanylyl cyclase-coupled receptor A. Immunol. (2003) 170:5869–5875.
   Web of Science ®Google Scholar
• KOPRAK S, STARUCH MJ, DUMONT FJ: A specific inhibitor of the p38 mitogen activated protein kinase affects differentially the production of various cytokines by activated human T cells: dependence on CD28 signaling and preferential inhibition of IL-10 production. Cell. Immunol. (1999) 192:87–95.
   PubMed Web of Science ®Google Scholar
• FEITO MJ, VASCHETTO R, CRIADO G et al.: Mechanisms of H4/ICOS costimulation: effects on proximal TCR signals and MAP kinase pathways. Eur.j Immunol. (2003) 33:204–214.
   PubMed Web of Science ®Google Scholar
• RAFIQ K, CHARITIDOU L, BULLENS DM et al.: Regulation of the IL-10 production by human T cells. Scand. Immunol. (2001) 53:139–147.
   PubMed Web of Science ®Google Scholar
• HOLM AM, AUKRUST P, AANDAHL EM et al.: Impaired secretion of IL-10 by T cells from patients with common variable immunodeficiency - involvement of protein kinase A Type I. Immunol. (2003) 170:5772–5777.
   Web of Science ®Google Scholar
• DUMONT FJ, STARUCH MJ, FISCHER P, DASILVA C, CAMACHO R: Inhibition of T cell activation by pharmacologic disruption of the MEK1/ ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production. J. Itninunol. (1998) 160:2579–2589.
   PubMed Web of Science ®Google Scholar
• BODMAN-SMITH MD, CORRIGALL VM, KEMENY DM, PANAYI GS: BiP, a putative autoantigen in rheumatoid arthritis, stimulates IL-10-producing CD8-positive T cells from normal individuals. Rheumatology (2003) 42:637–644.
   PubMed Web of Science ®Google Scholar
• D'AGOSTINO P, FERLAZZO V, MILANO S et al: Anti-inflammatory effects of chemically modified tetracyclines by the inhibition of nitric oxide and interleukin-12 synthesis in J774 cell line. Int. Immunopharmacol (2001) 1:1765–1776.
   PubMed Web of Science ®Google Scholar
• RAMAMURTHY NS, RIFKIN BR, GREENWALD RA et al.: Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: a comparison of 6 chemically modified tetracyclines.' Periodontol (2002) 73:726–734.
   PubMed Web of Science ®Google Scholar
• GROHMANN U, VAN SNICK J, CAMPANILE F et al.: IL-9 protects mice from Gram-negative bacterial shock: suppression of TNF-a, IL-12, and IFN-y, and induction of IL-10. I. Immunol. (2000) 164:4197–4203.
   PubMed Web of Science ®Google Scholar
• DEMOULIN JB, VAN ROOST E, STEVENS M, GRONER B, RENAULD JC: Distinct roles for STAT1, STAT3, and STAT5 in differentiation gene induction and apoptosis inhibition by interleukin-9." Biol. Chem. (1999) 274:25855–25861.
   PubMed Web of Science ®Google Scholar
• DUMONT FJ: Modulation of TH1 and TH2 responses for immunotherapy. Expert Opin. Titer. Patents (2002) 12:341–367.
   Web of Science ®Google Scholar
• AUKRUST P, WERGEDAHL H, MULLER F et al.: Immunomodulating effects of 3-thia fatty acids in activated peripheral blood mononuclear cells. Eur. Gin. Invest. (2003) 33:426–433.
   PubMed Web of Science ®Google Scholar
• MARUYAMA S, KATO K, KODAMA M et al.: Fenofibrate, a peroxisome proliferator-activated receptor a activator, suppresses experimental autoimmune myocarditis by stimulating the interleukin-10 pathway in rats. Atheroscler. Thromb. (2002) 9:87–92.
   Google Scholar
• SMITH SR, TERMINELLI C, DENHARDT G: Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J. Pharmacol. Exp. Titer: (2000) 293:136–150.
   Google Scholar
• BOURRIE B, BRIBES E, DE NYS N et al: 55R125329A, a high affinity 6 receptor ligand with potent anti-inflammatory properties. Eur. Pharmacol. (2002) 456:123–131.
   PubMed Web of Science ®Google Scholar
• ZHU LX, SHARMA S, GARDNER B et al: IL-10 mediates 61 receptor-dependent suppression of antitumor immunity. Immunol. (2003) 170:3585–3591.
   Web of Science ®Google Scholar
• CURIEL-LEWANDROWSKI C, VENNA SS, ELLER MS et al.: Inhibition of the elicitation phase of contact hypersensitivity by thymidine dinucleotides is in part mediated by increased expression of interleukin-10 in human keratinocytes. Exp. Dermatol. (2003) 12:145–152.
   PubMed Web of Science ®Google Scholar
• KATAYAMA T, HAYASHI Y, NAGAHIRA K et al.: Imidocarb, a potent anti-protozoan drug, up-regulates interleukin-10 production by murine macrophages. Biochem. Biophys. Res. Commun. (2003) 309:414–418.
   PubMed Web of Science ®Google Scholar
• VIEIRA PL, HEYSTEK HC, WORMMEESTER J, WIERENGA EA, KAPSENBERG ML: Glatiramer acetate (copolymer-1, copaxone) promotes TH2 cell development and increased IL-10 production through modulation of dendritic cells. .1 Immunol. (2003) 170:4483–4488.
   PubMed Web of Science ®Google Scholar
• BENNASSER Y, BAHRAOUI E: HIV-1 Tat protein induces interleukin-10 in human peripheral blood monocytes: involvement of protein kinase C-PII and -8. FASEB J. (2002) 16:546–554.
   PubMed Web of Science ®Google Scholar
• FERLAZZO V, D'AGOSTINO p, MILANO S et al: Anti-inflammatory effects of annexin-1: stimulation of IL-10 release and inhibition of nitric oxide synthesis. Int. Immunopharmacol. (2003) 3:1363–1369.
   PubMed Web of Science ®Google Scholar
• WALTERSCHEID JP, ULLRICH SE, NGHIEM DX: Platelet-activating factor, a molecular sensor for cellular damage, activates systemic immune suppression. J. Exp. Med. (2002) 195:171–179.
   PubMed Web of Science ®Google Scholar
• NOLAN Y, MINOGUE A, VEREKER E et al.: Attenuation of LPS-induced changes in synaptic activity in rat hippocampus by Vasogen's Immune Modulation Therapy. Neuroimmunomodulation (2002) 10:40–46.
   PubMed Web of Science ®Google Scholar
• ESKDALE J, KEIJSERS V, HUIZINGA T, GALLAGHER G: Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. Genes Litman. (1999) 1:151–155.
   Web of Science ®Google Scholar
• REUSS E, FIMMERS R, KRUGER A et al.: Differential regulation of interleukin-10 production by genetic and environmental factors - a twin study. Genes Immun. (2002) 3:407–413.
   PubMed Web of Science ®Google Scholar
• GIBSON AW, EDBERG JC, WU J et al.: Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. Immunol. (2001) 166:3915–3922.
   Web of Science ®Google Scholar
• YEE LJ, TANG J, GIBSON AW et al: Interleukin-10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology (2001) 33:708–712.
   PubMed Web of Science ®Google Scholar
• CONSTANTINI PK, WAWRZYNOWICZ-SYCZEWSKA M, CLARE M et al.: Interleuldn-1, interleukin-10 and tumour necrosis factor-a gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to a-interferon therapy. Liver (2002) 22:404–412.
   PubMedGoogle Scholar
• KNAPP S, HENNIG BJ, FRODSHAM AJ et al.: Interleukin- 10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics (2003). [Electronically published ahead of print].
   Google Scholar
• WHITTINGTON HA, FREEBURN RW, GODINHO SI et al.: Analysis of an IL-10 polymorphism in idiopathic pulmonary fibrosis. Genes Inman. (2003) 4:258–264.
   Web of Science ®Google Scholar
• VAN DER LINDE K, BOOR PP, SANDKUIJL LA et al: A Gly15Arg mutation in the interleukin-10 gene reduces secretion of interleukin-10 in Crohn disease. Scand. Gastroenterol (2003) 38:611–617.
   PubMed Web of Science ®Google Scholar
• AWOMOYI AA, MARCHANT A, HOWSON JM et al: Interleuldn- 10, polymorphism in SLC11A1 (formerly NRAMP1), and susceptibility to tuberculosis. J. Infect. Dis. (2002) 186:1808–1814.
   PubMed Web of Science ®Google Scholar
• KOJIMA Y, KINOUCHI Y, TAKAHASHI S et al: Inflammatory bowel disease is associated with a novel promoter polymorphism of natural resistance-associated macrophage protein 1 (NRAMP1) gene. Tissue Antigens (2001) 58:379–384.
   PubMed Web of Science ®Google Scholar
• LIU Y, WEI SH, HO AS, DE WAAL MALEFYT R, MOORE KW: Expression cloning and characterisation of a human IL-10 receptor. Thrimunol (1994) 152: 1821-1829.
   Google Scholar
• CREPALDI L, GASPERINI S, LAPINET JA et al.: Up-regulation of IL-10R1 expression is required to render human neutrophils fully responsive to IL-10. J. Immunol (2001) 167:2312–2322.
   PubMed Web of Science ®Google Scholar
• DINGY, QIN L, ZAMARIN D et al: Differential IL-10R1 expression plays a critical role in IL-10-mediated immune regulation. J. bninunol. (2001) 167:6884–6892.
   Google Scholar
• ••The cell surface density of IL-10R1 expression determines the pattern of cellular responses to IL–10.
   Google Scholar
• CATTARUZZA M, SLODOWSKI W, STOJAKOVIC M, KRZESZ R, HECKER M: Interleukin-10 induction of nitric oxide synthase expression attenuates CD40-mediated interleukin-12 synthesis in human endothelial cells. J. Biol. Chem. (2003). [Electronically published ahead of print].
   Google Scholar
• GASCHE C, GRUNDTNERP, ZWIRN P et al.: Novel variants of the IL-10 receptor 1 affect inhibition of monocyte TNF-a production. J. Immunol (2003) 170:5578–5582.
   PubMed Web of Science ®Google Scholar
• REINISCH W, VERMEIRE S, SHAW SH et al: Novel IL-10R1 cSNPs protect from ulcerative colitis. Gastroenterology (2002) 122:A–300.
   Web of Science ®Google Scholar
• KOTENKO SV, KRAUSE CD, IZOTOVA LS et al.: Identification and functional characterisation of a second chain of the interleukin-10 receptor complex. EMBO J. (1997) 16:5894–5903.
   PubMed Web of Science ®Google Scholar
• TAKEDA K, CLAUSEN BE, KAISHO T et al.: Enhanced TH1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity (1999) 10:39–49.
   PubMed Web of Science ®Google Scholar
• RILEY JK, TAKEDA K, AKIRA S, SCHREIBER RD: Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. J. Biol. Chem. (1999) 274:16513–16521.
   Google Scholar
• KOBAYASHI M, KWEON MN, KUWATA H et al.: Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J. Chia. Invest. (2003) 111:1297–1308.
   PubMed Web of Science ®Google Scholar
• LANG R, PATEL D, MORRIS JJ, RUTSCHMAN RL, MURRAY PJ: Shaping gene expression in activated and resting primary macrophages by IL-10. Immunol (2002) 169:2253–2263.
   Web of Science ®Google Scholar
• DING Y, CHEN D, TARCSAFALVI A et al.: Suppressor of cytokine signaling 1 inhibits IL-10-mediated immune responses. Immunol (2003) 170:1383–1391.
   Web of Science ®Google Scholar
• BERLATO C, CASSATELLA MA, KINJYO I et al.: Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharide-induced macrophage activation. Immunol (2002) 168:6404–6411.
   Web of Science ®Google Scholar
• NIEMAND C, NIMMESGERN A, HAAN S et al.: Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. Immunol (2003) 170:3263–3272.
   Web of Science ®Google Scholar
• YASUKAWA H, OHISHI M, MORI H et al.: IL-6 induces an anti-inflammatory response in the absence of 50053 in macrophages. Nat. Immunol (2003) 4:551–556.
   PubMed Web of Science ®Google Scholar
• SCHOTTELIUS AJ, MAYO MW, SARTOR RB, BALDWIN ASJ: Interleukin-10 signaling blocks inhibitor of lcB kinase activity and nuclear factor lcB DNA binding. J. Biol. Chem. (1999) 274:31868–31874.
   PubMed Web of Science ®Google Scholar
• TABARY O, MUSELET C, ESCOTTE S et al: Interleukin-10 inhibits elevated chemokine interleukin-8 and regulated on activation normal T cell expressed and secreted production in cystic fibrosis bronchial epithelial cells by targeting the IicB kinase a/13 complex. Am. J. Pathol (2003) 162:293–302.
   PubMed Web of Science ®Google Scholar
• YU Z, ZHANG W, KONE BC: Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor lcB. Biochem. (2002) 367:97–105.
   Google Scholar
• KUWATA H, WATANABE Y, MIYOSHI H et al.: IL-10-inducible Bc1-3 negatively regulates LPS-induced TNF-a production in macrophages. Blood (2003) . [Electronically published ahead of print.]
   Google Scholar
• •Evidence that Bd-3 is induced by IL-10 and mediates the inhibition of TNF-a expression by blocking NF-icB DNA-binding.
   Google Scholar
• BERREBI D, BRUSCOLI S, COHEN N et al.: Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10. Blood (2003) 101:729–738.
   PubMed Web of Science ®Google Scholar
• •Reports that IL-10 stimulates the expression of the glucocorticoid-induced leucine zipper, which may mediate anti-inflammatory effects.
   Google Scholar
• KONTOYIANNIS D, KOTLYAROV A, CARBALLO E et al.: Interleukin-10 targets p38 MAPK to modulate ARE-dependent TNF mRNA translation and limit intestinal pathology. EMBO (2001) 20:3760–3770.
   PubMed Web of Science ®Google Scholar
• DENYS A, UDALOVA IA, SMITH C et al.: Evidence for a dual mechanism for IL-10 suppression of TNF-a production that does not involve inhibition of p38 mitogen-activated protein kinase or NF-icB in primary human macrophages. Immunol (2002) 168:4837–4845.
   Web of Science ®Google Scholar
• LEE TS, CHAU LY: Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat. Med. (2002) 8:240–246.
   PubMed Web of Science ®Google Scholar
• CAO S, LIU J, CHESI M et al.: Differential regulation of IL-12 and IL-10 gene expression in macrophages by the basic leucine zipper transcription factor c-Maf fibrosarcoma. Immunol (2002) 169:5715–5725.
   Web of Science ®Google Scholar
• PETIT-BERTRON AF, FITTING C, CAVAILLON JM, ADIB-CONQUY M: Adherence influences monocyte responsiveness to interleukin-10. Leukoc. Biol. (2003) 73:145–154.
   PubMed Web of Science ®Google Scholar
• OTTERBEIN LE, SOARES MP, YAMASHITA K, BACH FH: Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol (2003) 24:449–455.
   PubMed Web of Science ®Google Scholar
• WILLIAMS L, LALI F, CLARKE C, BRENNAN F, FOXWELL B: Interleukin-10 modulation of tumour necrosis factor receptors requires tyrosine kinases but not the PI 3-kinase/p70 S6 kinase pathway. Cytokine (2000) 12:934–943.
   PubMed Web of Science ®Google Scholar
• SHIROISHI M, TSUMOTO K, AMANO K et al.: Human inhibitory receptors Ig-like transcript 2 (Iur2) and ILT4 compete with CD8 for MHC Class I binding and bind preferentially to HLA-G. Proc. Nati Acad. Sci. USA (2003) 100:8856–8861.
   PubMed Web of Science ®Google Scholar
• GROUX H, O'GARRA A, BIGLER M et al.: A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature (1997) 389:737–742.
   Google Scholar
• •First description of Trl cells, a unique subset of regulatory T cells induced by IL-10.
   Google Scholar
• COTTREZ F, HURST SD, COFFMAN RL, GROUX H: T regulatory cells 1 inhibit a TH2-specific response M vivo. J. Immunol. (2000) 165:4848–4853.
   PubMed Web of Science ®Google Scholar
• BACCHETTA R, SARTIRANA C, LEVINGS MK et al.: Growth and expansion of human T regulatory Type 1 cells are independent from TCR activation but require exogenous cytokines. Eur.j Immunol (2002) 32:2237–2245.
   PubMed Web of Science ®Google Scholar
• BARRAT FJ, CUA DJ, BOONSTRA A et al: hi vitro generation of interleukin-10-producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by T helper Type 1 (TH1)- and T2-inducing cytokines. I Exp. Med. (2002) 195:603–616.
   PubMed Web of Science ®Google Scholar
• LEVINGS MK, SANGREGORIO R, GALBIATI F et al.: IFN-a and IL-10 induce the differentiation of human Type 1 T regulatory cells. J. Immunol (2001) 166:5530–5539.
   PubMed Web of Science ®Google Scholar
• LEVINGS MK, BACCHETTA R, SCHULZ U, RONCAROLO MG: The role of IL-10 and TGF-P in the differentiation and effector function of T regulatory cells. Int. Arch. Allergy Appl. Immunol. (2002) 129:263–276.
   Google Scholar
• Ha CHEN ZM, O'SHAUGHNESSY MJ, GRAMAGLIA I et al.: IL-10 and TGF-B induce alloreactive CD4+CD25- T cells to acquire regulatory cell function. Blood (2003) 101:5076–5083.
   Google Scholar
• WAKKACH A, COTTREZ F, GROUX H: Differentiation of regulatory T cells 1 is induced by CD2 costimulation. Immunol (2001) 167:3107–3113.
   Web of Science ®Google Scholar
• KEMPER C, CHAN AC, GREEN JM et al.: Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature (2003) 421:388–392.
   PubMed Web of Science ®Google Scholar
• SATOGUINA J, MEMPEL M, LARBI J et al.: Antigen-specific T regulatory-1 cells are associated with immunosuppression in a chronic helminth infection (onchocerciasis). Microbes Infect. (2002) 4:1291–1300.
   PubMed Web of Science ®Google Scholar
• JUMP RL, LEVINE AD: Murine Peyer's patches favor development of an IL-10-secreting, regulatory T cell population. J.Immunol. (2002) 168:6113–6119.
   PubMed Web of Science ®Google Scholar
• MCGUIRK P, MCCANN C, MILLS KH: Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin-10 production by dendritic cells: a novel strategy for evasion of protective T helper Type 1 responses by Bordetella pertusii I Exp. Med. (2002) 195:221–231.
   Web of Science ®Google Scholar
• MAURER M, SEIDEL-GUYENOT W, METZ M, KNOP J, STEINBRINK K: Critical role of IL-10 in the induction of low zone tolerance to contact allergens. Clin. Invest. (2003). [Electronically published ahead of print.]
   Google Scholar
• WAKKACH A, FOURNIER N, BRUN V et al.: Characterisation of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity (2003) 18:605–617.
   PubMed Web of Science ®Google Scholar
• •A subset of immature plasmacytoid DCs generated in the presence of IL-10 induce the differentiation of Trl cells.
   Google Scholar
• SATO K, YAMASHITA N, BABA M, MATSUYAMA T: Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood (2003) 101:3581–3589.
   PubMed Web of Science ®Google Scholar
• MARTIN E, O'SULLIVAN B, LOW P, THOMAS R: Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity(2003)18:b55–b67.
   Web of Science ®Google Scholar
• •Demonstrates that antigen-exposed DCs in which RelB function is inhibited can promote the differentiation of IL-10-producing regulatory T cells.
   Google Scholar
• JONULEIT H, SCHMITT E, STEINBRINK K, ENK AH: Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol (2001) 22:394–400.
   PubMed Web of Science ®Google Scholar
• MAHNKE K, QIAN Y, KNOPJ, ENK AH: Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells. Blood (2003) 101:4862–4869.
   PubMed Web of Science ®Google Scholar
• KUWANA M: Induction of anergic and regulatory T cells by plasmacytoid dendritic cells and other dendritic cell subsets. Hum. Immunol (2002) 63:1156–1163.
   PubMed Web of Science ®Google Scholar
• AKBARI O, DEKRUYFF RH, UMETSU DT: Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat. Immunol. (2001) 2:725–731.
   PubMed Web of Science ®Google Scholar
• AKBARI O, FREEMAN GJ, MEYER EH et al.: Antigen-specific regulatory T cells develop via the ICOS/ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat. Med. (2002) 8:1024–1032.
   PubMed Web of Science ®Google Scholar
• •Reports that T cell costirnulation via the IC OS/IC OS-ligand pathway is involved in the development of Trl cells induced by mature pulmonary DCs.
   Google Scholar
• WITSCH EJ, PEISER M, HUTLOFF A et al.: ICOS and CD28 reversely regulate IL-10 on reactivation of human effector T cells with mature dendritic cells. Eur. Immunol. (2002) 32:2680–2686.
   PubMed Web of Science ®Google Scholar
• DHODAPKAR MV, STEINMAN RM: Antigen-bearing immature dendritic cells induce peptide-specific CD8 + regulatory T cells in vivoin humans. Blood (2002) 100:174–177.
   PubMed Web of Science ®Google Scholar
• GILLIET M, LIU YJ: Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. Exp. Med. (2002) 195:695–704.
   PubMed Web of Science ®Google Scholar
• STEINBRINK K, GRAULICH E, KUBSCH S, KNOP J, ENK AH: CD4+ and CD8 + anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood (2002) 99:2468–2476.
   PubMed Web of Science ®Google Scholar
• KUBSCH S, GRAULICH E, KNOP J, STEINBRINK K: Suppressor activity of anergic T cells induced by IL-10-treated human dendritic cells: association with IL-2-and CTLA-4-dependent G1 arrest of the cell cycle regulated by p27Kipl. Eur. Immunol. (2003) 33:1988–1997.
   PubMed Web of Science ®Google Scholar
• READ, VAN KOOTEN C, VAN MEIJGAARDEN KE et al: Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10. Blood (2000) 95:3162–3167.
   PubMed Web of Science ®Google Scholar
• MUNN DH, SHARMA MD, LEE JR et al.: Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science (2002) 297: 1867-1870.
   Google Scholar
• WRAITH DC: Role of interleukin-10 in the induction and function of natural and antigen-induced regulatory T cells. Autonninunity(2003) 20:273–275.
   Web of Science ®Google Scholar
• SUNDSTEDT A, O'NEILL EJ, NICOLSON KS, WRAITH DC: Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo. brununol. (2003) 170:1240–1248.
   Google Scholar
• OH JVV, SEROOGY CM, MEYER EH et al.: CD4 T-helper cells engineered to produce IL-10 prevent allergen-induced airway hyperreactivity and inflammation. J. Allergy Cl/n. Immunol. (2002)110:460–468.
   PubMed Web of Science ®Google Scholar
• WEINER HL: Induction and mechanism of action of transforming growth factor-I3-secreting TH3 regulatory cells. brununol. Rev (2001) 182:207–214.
   Google Scholar
• LEVINGS MK, SANGREGORIO R, SARTIRANA C et al: Human CD25±CD4+ T suppressor cell clones produce transforming growth factor-I3, but not interleukin-10, and are distinct from Type 1 T regulatory cells. J. Exp. Med. (2002) 196:1335–1346.
   PubMed Web of Science ®Google Scholar
• SHEVACH EM: CD4+CD25+ suppressor T cells: more questions than answers. Nat. Rev Innnunol. (2002) 2:389–400.
   PubMed Web of Science ®Google Scholar
• FONTENOT JD, GAVIN MA, RUDENSKY AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. brununol. (2003) 4:330–336.
   PubMed Web of Science ®Google Scholar
• HORT S, NOMURA T, SAKAGUCHI S: Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 299:1057–1061.
   PubMed Web of Science ®Google Scholar
• KHATTRI R, COX T, YASAYKO SA, RAMSDELL F: An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat. Innnunol. (2003) 4:337–342.
   PubMed Web of Science ®Google Scholar
• HOFFMANN P, ERMANN J, EDINGER M, FATHMAN CG, STROBER S: Donor-type CD4+CD25+ regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. I Exp. Med. (2002) 196:389–399.
   PubMed Web of Science ®Google Scholar
• BELKAID Y, PICCIRILLO CA, MENDEZ S, SHE VACH EM, SACKS DL: CD4+CD25+ regulatory T cells control Leishinania major persistence and immunity. Nature (2002) 420:502–507.
   PubMed Web of Science ®Google Scholar
• MALOY KJ, SALAUN L, CAHILL R et al.: CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J. Exp. Med (2003) 197:111–119.
   PubMed Web of Science ®Google Scholar
• JONULEIT H, SCHMITT E, KAKIRMAN H et al: Infectious tolerance: human CD25(±) regulatory T cells convey suppressor activity to conventional CD4+ T helper cells. J. Exp. Med. (2002) 196:255–260.
   PubMed Web of Science ®Google Scholar
• DIE CKMANN D, BRUETT CH, PLOETTNER H, LUTZ MB, SCHULER G: Human CD4+CD25+ regulatory, contact-dependent T cells induce interleukin-1-producing, contact-independent Type 1-like regulatory T cells. J. Exp. Med. (2002) 196:247–253.
   PubMed Web of Science ®Google Scholar
• ROSENBLUM IY, JOHNSON RC, SCHMAHAI TJ: Preclinical safety evaluation of recombinant human interleukin-10. Regal Toxicol Pharinacol. (2002) 35:56–71.
   PubMed Web of Science ®Google Scholar
• CHERNOFF AE, GRANOWITZ EV, SHAPIRO L et al.: A randomised, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. Innnunol. (1995) 154:5492–5499.
   Google Scholar
• WISSING KM, MORELON E, LEGENDRE C et al: A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy. Transplantation (1997) 64:999–1006.
   PubMed Web of Science ®Google Scholar
• PAJKRT D, CAMOGLIO L, TIEL-VAN BUUL MC et al.: Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administration. Innnunol. (1997) 158:3971–3977.
   Google Scholar
• PAJKRT D, VAN DER POLL T, LEVI M et al.: Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. Blood (1997) 89:2701–2705.
   Google Scholar
• OLSZYNA DP, PAJKRT D, LAUW FN, VAN DEVENTER SJ, VAN DER POUT: Interleukin-10 inhibits the release of CC chemokines during human endotoxemia. J. Infect. Dis. (2000) 181:613–620.
   PubMed Web of Science ®Google Scholar
• LAUW FN, PAJKRT D, HACK CE et al: Proinflammatory effects of IL-10 during human endotoxemia. Innnunol. (2000) 165:2783–2789.
   Google Scholar
• •Demonstrates that a high dose of IL-10 augments IFN-y production after LPS injection in healthy subjects.
   Google Scholar
• POD OLSKY DK: Inflammatory bowel disease. N Engl. J. Med. (2002) 8:417–429.
   Google Scholar
• MADSEN KL: Inflammatory bowel disease: lessons from the IL-10 gene-deficient mouse. Clin. Invest. Med. (2001) 24:250–257.
   PubMed Web of Science ®Google Scholar
• MAHLER M, LEITER EH: Genetic and environmental context determines the course of colitis developing in IL-10-deficient mice. Intim-on. Bowel Dis. (2002) 8:347–355.
   PubMed Web of Science ®Google Scholar
• LINDSAY JO, CIESIELSKI CJ, SCHEININ T, HODGSON HJ, BRENNAN FM: The prevention and treatment of murine colitis using gene therapy with adenoviral vectors encoding IL-10. J. binnunol. (2001) 166:7625–7633.
   Google Scholar
• TOMOYOSE M, MITSUYAMA K, ISHIDA H, TOYONAGA A, TANIKAWA K: Role of interleukin-10 in a murine model of dextran sulfate sodium-induced colitis. Scand. Gastroenterol (1998) 33:435–430.
   PubMed Web of Science ®Google Scholar
• LINDSAY J, VAN MONTFRANS C, BRENNAN F et al.: IL-10 gene therapy prevents TNBS-induced colitis. Gene Ther: (2002) 9: 1715-1721.
   Google Scholar
• FEDORAK RN, GANGL A, ELSON CO et al.: Recombinant human interleukin-1 O in the treatment of patients with mild-to-moderately active Crohn's disease.The interleukin-10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology (2000) 119:1473–1782.
   Google Scholar
• •Evaluation of rhIL-10 in CD patients.
   Google Scholar
• SCHREIBER S, FEDORAK RN, NIELSEN OH et al.: Safety and efficacy of recombinant human interleukin-10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 119:1461–1472.
   Google Scholar
• •Evaluation of rhIL-10 in CD patients.
   Google Scholar
• COLOMBEL JF, RUTGEERTS P, MALCHOW H et al: Interleuldn-10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut (2001) 49:42–46.
   PubMed Web of Science ®Google Scholar
• MERESSE B, RUTGEERTS P, MALCHOW H et al.: Low ileal interleukin 10 concentrations are predictive of endoscopic recurrence in patients with Crohn's disease. Gut (2002) 50:25–28.
   PubMed Web of Science ®Google Scholar
• TILG H, VAN MONTFRANS C, VAN DEN ENDE A et al: Treatment of Crohn's disease with recombinant human interleukin-10 induces the proinflammatory cytokine interferon-y. Gut (2002) 50:191–195.
   PubMed Web of Science ®Google Scholar
• ••Demonstrates that high doses of IL-10upregulate the production of IFN-y in CD patients, an effect that may be responsible for the lack of therapeutic efficacy of this treatment.
   Google Scholar
• SCHMIT A, CAROL M, ROBERT F et al.: Dose-effect of interleukin-10 and its immunoregulatory role in Crohn's disease. Ear: Cytokine Netw. (2002) 13:298–305.
   PubMed Web of Science ®Google Scholar
• GOLDBACH-MANSKY R, LIPSKY PE: New concepts in the treatment of rheumatoid arthritis. Ann. Rev Med. (2002) 54:197–216.
   Web of Science ®Google Scholar
• VERVOORDELDONK MJ, TAK PP: Cytokines in rheumatoid arthritis. Carr: Rheumatol Rep. (2002) 4:208–217.
   PubMedGoogle Scholar
• CUSH JJ, SPLAWSKI JB, THOMAS R et al.: Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum. (1995) 38:96–104.
   PubMed Web of Science ®Google Scholar
• MOLLER B, NGUYEN TT, KESSLER U et al: Interleukin-10 expression: is there a neglected contribution of CD8+ T cells in rheumatoid arthritis joints? Clin. Exp. Rheumatol (2002) 20:813–822.
   PubMedGoogle Scholar
• VERHOEF CM, VAN ROON JA, VIANEN ME, BIJLSMA JW, LAFEBER FP: Interleuldn-10 (IL-10), not IL-4 or interferon-y production, correlates with progression of joint destruction in rheumatoid arthritis. Rheumatol (2001) 28: 1960-1966.
   Google Scholar
• LARD LR, VAN GAALEN FA, SCHONKEREN JJ et al: Association of the -2849 interleukin-10 promoter polymorphism with autoantibody production and joint destruction in rheumatoid arthritis. Arthritis Rheum. (2003) 48:1841–1848.
   PubMedGoogle Scholar
• KATSIKIS PD, CHU CQ, BRENNAN FM, MAINI RN, FELDMANN M: Immunoregulatory role of interleukin-10 in rheumatoid arthritis. Exp. Med. (1994) 179:1517–1527.
   PubMed Web of Science ®Google Scholar
• HOLMDAHL R, BOCKERMANN R, BACKLUND J, YAMADA H: The molecular pathogenesis of collagen-induced arthritis in mice - a model for rheumatoid arthritis. Ageing Res. Rev (2002) 1:135–147.
   PubMed Web of Science ®Google Scholar
• WALMSLEY M, KATSIKIS PD, ABNEY E et al.: Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritic Rheum. (1996) 39:495–503.
   PubMed Web of Science ®Google Scholar
• JOOSTEN LA, LUBBERTS E, DUREZ P et al.: Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritic Rheum. (1997) 40:249–260.
   Google Scholar
• QUATTROCCHI E, DALLMAN MJ, DHILLON AP et al: Murine IL-10 gene transfer inhibits established collagen-induced arthritis and reduces adenovirus-mediated inflammatory responses in mouse liver." Immunol (2001) 166:5970–5978.
   PubMed Web of Science ®Google Scholar
• SAIDENBERG-KERMANAC'H N, BESSIS N, DELEUZE Vet al.: Efficacy of interleukin-10 gene electrotransfer into skeletal muscle in mice with collagen-induced arthritis. I Gene Med. (2003) 5:164–171.
   Google Scholar
• CUZZOCREA S, MAZZON E, DUGO L et al.: Absence of endogeneous interleukin-10 enhances the evolution of murine Type-II collagen-induced arthritis. Eur. Cytokine Netw. (2001) 12:568–580.
   PubMed Web of Science ®Google Scholar
• FINNEGAN A, KAPLAN CD, CAO Y et al.: Collagen-induced arthritis is exacerbated in IL-10-deficient mice. Arthritic Res. The]: (2003) 5:R18–R24.
   Google Scholar
• MAINI RN, PAULUS H, BREEDVELD FC, AL E: rHuIL-10 in subjects with active rheumatoid arthritis (RA): a Phase I and cytokine response study. Arthritic Rheum. (1997) 40:S224.
   Web of Science ®Google Scholar
• VAN ROON J, WIJNGAARDEN S, LAFEBER FP et al.: Interleuldn-10 treatment of patients with rheumatoid arthritis enhances Fcy receptor expression on monocytes and responsiveness to immune complex stimulation.' Rheumatol (2003) 30:648–651.
   Web of Science ®Google Scholar
• ••IL-10 augments the expression ofFey receptors on monocytes/ macrophages, an effect that may potentiate immune complex-mediated inflammation and counteract the otherwise anti-inflammatory action of this cytokine.
   Google Scholar
• GERBER JS, MOSSER DM: Stimulatory and inhibitory signals originating from the macrophage Fcy receptors. Microbes Infect. (2001) 3:131–139.
   PubMed Web of Science ®Google Scholar
• JI JD, TASSIULAS I, PARK-MIN KH et al.: Inhibition of interleukin-10 signaling after Fc receptor ligation and during rheumatoid arthritis. I Exp. Med. (2003) 197:1573–1583.
   PubMed Web of Science ®Google Scholar
• ••Shows that IL-10 signalling inmacrophages is inhibited by ligation of Fc receptors with immune complexes. This may contribute to the pathogenesis of RA.
   Google Scholar
• VAN ROON JA, BIJLSMA JW, LAFEBER FP: Suppression of inflammation and joint destruction in rheumatoid arthritis may require a concerted action of TH2 cytokines. Carr. Opin. Investig. Drugs (2002) 3:1011–1016.
   PubMedGoogle Scholar
• WIJNGAARDEN S, VAN ROON JA, BIJSMA JW, VAN DE WINKEL JG, LAFEBER FP: Fcy receptor expression levels on monocytes are elevated in rheumatoid arthritis patients with high erythrocyte sedimentation rate who do not use anti-rheumatic drugs. Rheumatology (2003) 42:681–688.
   PubMed Web of Science ®Google Scholar
• WEINBLATT ME, AL E: RhuIL-10 (Tenovil) plus methotrexate in active rheumatoid arthritis (RA): a Phase I/II study. Arthritic Rheum. (1999) 42:S170.
   Google Scholar
• SARAVANAN V, HAMILTON J: Advances in the treatment of rheumatoid arthritis: old versus new therapies. Expert Opin. Pharmacother: (2002) 3:845–856.
   PubMedGoogle Scholar
• ASADULLAH K, VOLK HD, STERRY W: Novel immunotherapies for psoriasis. Trends Immunol (2002) 23:47–53.
   PubMed Web of Science ®Google Scholar
• AIBA S, UDDIN Z, NAKAGAWA S et al: Decreased IL-10 production by psoriatic peripheral blood mononuclear cells stimulated with streptococcal superantigen. Exp. Dermatol (2002) 11:337–343.
   PubMed Web of Science ®Google Scholar
• REICH K, GARBE C, BLASCHKE V et al.: Response of psoriasis to interleukin-10 is associated with suppression of cutaneous Type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J. Invest. Dermatol (2001) 116:319–329.
   PubMed Web of Science ®Google Scholar
• ASADULLAH K, FRIEDRICH M, HANNEKEN S et al: Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings. J. Invest. Dermatol (2001) 116:721–727.
   PubMed Web of Science ®Google Scholar
• MCINNES IB, ILLEI GG, DANNING CL et al.: IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. Immunol (2001) 167:4075–4082.
   Web of Science ®Google Scholar
• FRIEDRICH M, DOCKE WD, KLEIN A et al.: Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in psoriasis. J. Invest. Dermatol (2002) 118:672–677.
   PubMed Web of Science ®Google Scholar
• •Placebo-controlled trial of IL-10 in psoriasis.
   Google Scholar
• KIMBALL AB, KAWAMURA T, TEJURA K et at Clinical and immunologic assessment of patients with psoriasis in a randomised, double-blind, placebo-controlled trial using recombinant human interleukin-10. Arch. Dermatol (2002) 138:1341–1346.
   PubMed Web of Science ®Google Scholar
• •Placebo-controlled trial of IL-10 in psoriasis.
   Google Scholar
• KINGO K, KOKS S, SILM H, VASAR E: IL-10 promoter polymorphisms influence disease severity and course in psoriasis. Genes Irnmun. (2003) 4:455–457.
   PubMed Web of Science ®Google Scholar
• ZOU WG, WANG DS, LANG MF et al: Human interleukin-10 gene therapy decreases the severity and mortality of lethal pancreatitis in rats.' Surg. Res. (2002) 103:121–126.
   PubMed Web of Science ®Google Scholar
• DEMOLS A, VAN LAETHEM JL, QUERTINMONT E et al: Endogenous interleukin-10 modulates fibrosis and regeneration in experimental chronic pancreatitis. Am. .1. Physic] Gastrointest. Liver Physiol (2002) 282:G1105–G1112.
   Google Scholar
• DEMOLS A, DEVIERE J: New frontiers in the pharmacological prevention of post-ERCP pancreatitis: the cytokines. JOP (2003) 4:49–57.
   PubMedGoogle Scholar
• THOMPSON K, MALTBY J, FALLOWFIELD J et al: Interleuldn-10 expression and function in experimental murine liver inflammation and fibrosis. Hepatology (1998) 28: 1597-1606.
   Google Scholar
• LOUIS H, LE MOINE O, GOLDMAN M, DEVIERE J: Modulation of liver injury by interleukin-10. Acta Gastmenterol Belg. (2003) 66:7–14.
   PubMed Web of Science ®Google Scholar
• NELSON DR, LAUWERS GY, LAU JY, DAVIS GL: Interleukin-10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon non-responders. Gastroenterology (2000) 118:655–660.
   PubMed Web of Science ®Google Scholar
• BED OSSA P, PARADIS V: Approaches for treatment of liver fibrosis in chronic hepatitis C. Cl/n. Liver Dis. (2003) 7:195–210.
   PubMedGoogle Scholar
• LIECHTY KW, KIM HB, ADZICK NS, CROMBLEHOLME TM: Fetal wound repair results in scar formation in interleukin-10-deficient mice in a syngeneic murine model of scarless fetal wound repair. Pediam. &mg. (2000) 35:866–872.
   PubMed Web of Science ®Google Scholar
• BONFIELD TL, KONSTAN MW, BERGER M: Altered respiratory epithelial cell cytokine production in cystic fibrosis. Allergy Chia. Immunol (1999) 104:72–78.
   PubMed Web of Science ®Google Scholar
• SOLTYS J, BONFIELD T, CHMIEL J, BERGER M: Functional IL-10 deficiency in the lung of cystic fibrosis (cftr-/-) and IL-10 knockout mice causes increased expression and function of B7 costimulatory molecules on alveolar macrophages. Immunol (2002) 168: 1903-1910.
   Google Scholar
• CHMIEL JF, BERGER M, KONSTAN MW: The role of inflammation in the pathophysiology of CF lung disease. Chia. Rev Allergy Immunol (2002) 23:5–27.
   PubMed Web of Science ®Google Scholar
• ZHENG XX, STEELE AW, HANCOCK WW et al: A non-cytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice. Immunol (1997) 158:4507–4513.
   Web of Science ®Google Scholar
• FORTINBERRY H, WU J, ASIEDU C et al.: Recombinant rhesus macaque IL-10 fusion protein: a potential adjunct for tolerance induction strategies. Am.Transplant. (2003) 3. Abstract 459.
   Google Scholar
• MOLINEUX G: Pegylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treat. Rev. (2002) 28(Suppl.A):13–16.
   Google Scholar
• GLEHEN O, MITHIEUX F, TRAVERSE-GLEHEN A et al.: Enteral immunotherapy in the treatment of chronic enterocolitis in interleukin- 10-deficient mice. Hepatogastroenterology (2003) 50:670–675.
   PubMedGoogle Scholar
• LINDSAYJO, CIESIELSKI CJ, SCHEININ T, BRENNAN FM, HODGSON HJ: Local delivery of adenoviral vectors encoding murine interleukin- 10 induces colonic interleukin 10 production and is therapeutic for murine colitis. Gut (2003) 52:363–369 .
   PubMed Web of Science ®Google Scholar
• NAKASE H, OKAZAKI K, TABATA Y, CHIBA T: Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease. Gastroenterol (2003) 38:59–62.
   Web of Science ®Google Scholar
• VAN MONTFRANS C, RODRIGUEZ PENA MS, PRONK I et al.: Prevention of colitis by interleukin-10-transduced T lymphocytes in the SCID mice transfer model. Gastroenterology (2002) 123: 1865-1876.
   Google Scholar
• VAN MONTFRANS C, HOOIJBERG E, RODRIGUEZ PENA MS et al.: Generation of regulatory gut-homing human T lymphocytes using ex vivo interleukin-10 gene transfer. Gastroenterology (2002) 123:1877–1888.
   Google Scholar
• STEIDLER L, HANS W, SCHOTTE L et al.: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science (2000) 289:1352–1355.
   PubMed Web of Science ®Google Scholar
• ••Intragastric administration of Lactococcus lactis genetically engineered to secrete IL-10 reduced the incidence of intestinal inflammation in murine models of colitis.
   Google Scholar
• STEIDLER L, NEIRYNCK S, HUYGHEBAERT N et al: Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin-10. Nat. Biotechnol (2003) 21:785–789.
   PubMed Web of Science ®Google Scholar
• BRAAT H, PEPPELENBOSCH MP, HOMMES DW: Interleukin-10-based therapy for inflammatory bowel disease. Expert Opin. Biol. The]: (2003) 3:725–731.
   Google Scholar
• COLPAERT S, VANSTRAELEN K, LIU Z et al.: Decreased lamina propria effector cell responsiveness to interleukin-10 in ileal Crohn's disease. Chia. Immunol (2002) 102:68–76.
   PubMed Web of Science ®Google Scholar
• •Lamina propria monocytes from CD patients have reduced responsiveness to IL-10.
   Google Scholar
• ROBBINS PD, EVANS CH, CHERNAJOVSKY Y: Gene therapy for arthritis. Gene Ther. (2003) 10:902–911.
   PubMed Web of Science ®Google Scholar
• WHALEN JD, LECHMAN EL, CARLOS CA et al.: Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. I Immunol (1999) 162:3625–3632.
   PubMed Web of Science ®Google Scholar
• LUBBERTS E, JOOSTEN LA, VAN DEN BERSSELAAR L et al.: Intra-articular IL-10 gene transfer regulates the expression of collagen-induced arthritis (CIA) in the knee and ipsilateral paw. Chia. Exp. Immunol (2000) 120:375–383.
   Google Scholar
• MIAGKOV AV, VARLEY AW, MUNFORD RS, MAKAROV SS: Endogenous regulation of a therapeutic transgene restores homeostasis in arthritic joints.j Clin. Invest. (2002) 109:1223–1229.
   PubMed Web of Science ®Google Scholar
• ••Design of a recombinant adenoviralvector with an inflammation-inducible promoter controlling the expression of human IL-10 cDNA, such that this IL-10 transgene was induced in parallel with disease recurrence in a model of arthritis.
   Google Scholar
• SETOGUCHI K, MISAKI Y, ARAKI Y et al.: Antigen-specific T cells transduced with IL-10 ameliorate experimentally induced arthritis without impairing the systemic immune response to the antigen. Immunol. (2000) 165:5980–5986.
   Web of Science ®Google Scholar
• MAURI C, GRAY D, MUSHTAQ N, LONDEI M: Prevention of arthritis by interleukin-10 -producing B cells. J. Exp. Med. (2003) 197:489–501.
   PubMed Web of Science ®Google Scholar
• BRUNETTI M, MASCETRA N, MARTELLI N et al: Synergistic inhibitory activities of interleukin-10 and dexamethasone on human CD4+ T cells. Transplantation (2002) 74:1152–1158.
   PubMed Web of Science ®Google Scholar
• CHAKRABORTY A, JUSKO WJ: Pharmacodynamic interaction of recombinant human interleukin-10 and prednisolone using M vitro whole blood lymphocyte proliferation. J. Pharm. Sci. (2002) 91:1334–1342.
   PubMed Web of Science ®Google Scholar
• JUTEL M, AKDIS M, BUDAK F et al: IL-10 and TGF-I3 cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Ear: j Immunol (2003) 33:1205–1214.
   PubMed Web of Science ®Google Scholar
• KIM KN, WATANABE S, MA Yet al.: Viral IL-10 and soluble TNF receptor act synergistically to inhibit collagen-induced arthritis following adenovirus-mediated gene transfer. " Immunol (2000) 164:1576–1581.
   Google Scholar
• NEUMANN E, JUDEX M, KULLMANN F et al.: Inhibition of cartilage destruction by double gene transfer of IL-1Ra and IL-10 involves the activin pathway. Gene The]: (2002) 9:1508–1519.
   PubMed Web of Science ®Google Scholar
• ROGY MA, BEINHAUER BG, REINISCH W, HUANG L, POKIESER P: Transfer of interleukin-4 and interleukin-10 in patients with severe inflammatory bowel disease of the rectum. Hum. Gene Tiler: (2000) 11:1731–1741.
   Google Scholar
• VAN DE LOO FA, VAN DEN BERG WB: Gene therapy for rheumatoid arthritis. Lessons from animal models, including studies on interleukin-4, interleukin-10, and interleukin-1 receptor antagonist as potential disease modulators. Rheum. Dis. Clin. North Am. (2002) 28:127–149.
   Google Scholar
• VON HERRATH MG, HARRISON LC: Antigen-induced regulatory T cells in autoimmunity. Nat. Rev Immunol (2003) 3:223–232.
   PubMed Web of Science ®Google Scholar
• WOOD KJ, SAKAGUCHI S: Regulatory T cells in transplantation tolerance. Nat. Rev Immunol (2003) 3:199–210.
   PubMed Web of Science ®Google Scholar
• SEBASTIANI S, ALLAVENA P, ALBANESI C et al.: Chemokine receptor expression and function in CD4+ T lymphocytes with regulatory activity. I. Immunol (2001) 166:996–1002.
   PubMed Web of Science ®Google Scholar
• CONG Y, WEAVER CT, LAZENBY A, ELSON CO: Bacterial-reactive T regulatory cells inhibit pathogenic immune responses to the enteric flora. J. Immunol (2002) 169:6112–6119.
   PubMed Web of Science ®Google Scholar
• GRIFFIN MD, LUTZ W, PHAN VA et al.: Dendritic cell modulation by 1a,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc. Natl Acad. ScLUSA (2001) 98:6800–6805.
   PubMed Web of Science ®Google Scholar
• HEROLD KC, BURTON JB, FRANCOIS F et al.: Activation of human T cells by FcR non-binding anti-CD3 mAb, hOKT3y1 (Ala-Ala). J. Clin. Invest. (2003) 111:409–418.
   PubMed Web of Science ®Google Scholar
• BEEBE AM, CUA DJ, DE WAAL MALEFYT R: The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Cytokine Growth Factor Rev (2002) 13:403–412.
   PubMed Web of Science ®Google Scholar
• •A review of the evidence supporting a role for IL-10 in the pathogenesis of SLE and multiple sclerosis.
   Google Scholar
• D' ALFONSO S, GIORDANO M, MELLAI M et al.: Association tests with systemic lupus erythematosus (SLE) of IL-10 markers indicate a direct involvement of a CA repeat in the 5' regulatory region. Genes Immun. (2002) 3:454–463.
   Google Scholar
• RONNELID J, TEJDE A, MATHSSON L, NILSSON- EKDAHL K, NILSSON B: Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcyRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann. Rheum. Dis. (2003) 62:37–42.
   PubMed Web of Science ®Google Scholar
• •Immune complexes may induce IL-10 production in SLE, thereby contributing to perpetuation of the disease.
   Google Scholar
• LLORENTE L, RICHAUD-PATIN Y, GARCIA-PADILLA C et at Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. (2000) 43:1790–1800.
   PubMed Web of Science ®Google Scholar
• PERRIER S, SERRE AF, DUBOST JJ et al.: Increased serum levels of interleukin 10 in Sjogren's syndrome; correlation with increased IgGl. Rheumatol. (2000) 27:935–939.
   Web of Science ®Google Scholar
• FONT J, GARCIA-CARRASCO M, RAMOS-CASALS M et at The role of interleukin-10 promoter polymorphisms in the clinical expression of primary Sjogren's syndrome. Rheumatology (2002) 41:1025–1030.
   PubMed Web of Science ®Google Scholar
• ANAYAJM, CORREA PA, HERRERA M, ESKDALE J, GALLAGHER G: Interleukin 10 (IL-10) influences autoimmune response in primary Sjogren's syndrome and is linked to IL-10 gene polymorphism. J. Rheumatol. (2002) 29:1874–1876.
   PubMed Web of Science ®Google Scholar
• WATANABE N, IKUTA K, NISITANI S, CHIBA T, HONJO T: Activation and differentiation of autoreactive B-1 cells by interleukin-10 induce autoimmune haemolytic anaemia in Fas-deficient antierythrocyte immunoglobulin transgenic mice. " Exp. Med. (2002) 196:141–146.
   PubMed Web of Science ®Google Scholar
• OSTLIE NS, KARACHUNSKI PI, WANG W et al.: Transgenic expression of IL-10 in T cells facilitates development of experimental myasthenia gravis. I. Immunol (2001) 166:4853–4862.
   PubMed Web of Science ®Google Scholar
• LOPATIN U, YAO X, WILLIAMS RK et al.: Increases in circulating and lymphoid tissue interleukin-10 in autoimmune lymphoproliferative syndrome are associated with disease expression. Blood (2001) 97:3161–3170.
   PubMed Web of Science ®Google Scholar
• TURNER J, GONZALEZ-JUARRERO M, ELLIS DL et al: In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice. J. Innnunol. (2002) 169:6343–6351.
   Google Scholar
• MURRAY HW, MOREIRA AL, LU CM et al.: Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis. 1 Infect. Dis. (2003) 188:458–464.
   Google Scholar
• MOCELLIN S, PANELLI MC, WANG E, NAGORSEN D, MARINCOLA FM: The dual role of IL-10. Trends brununol. (2003) 24:36–43.
   PubMed Web of Science ®Google Scholar
• ••Review of the diverse roles of IL-10 in cancer.
   Google Scholar
• YANG AS, LATTIME EC: Tumor-induced interleukin-10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T cell responses. Cancer Res. (2003) 63:2150–2157.
   PubMed Web of Science ®Google Scholar
• SEGAL BM, GLASS DD, SHE VACH EM: IL-10-producing CD4+ T cells mediate tumor rejection. brununol. (2002) 168:1–4.
   Google Scholar
• FAYAD L, KEATING MJ, REUBEN JM et al.: Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood (2001) 97:256–263.
   PubMed Web of Science ®Google Scholar
• ORDEMANN J, JACOBI CA, BRAUMANN C et al: Immunomodulatory changes in patients with colorectal cancer. Int. 1 Colorectal Dis. (2002) 17:37–41.
   PubMed Web of Science ®Google Scholar
• GALIZIA G, ORDITURA M, ROMANO C et al.: Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin.(2002) 102:169–178.
   Google Scholar
• UWATOKO N, TOKUNAGA T, HATANAKA H et al.: Expression of interleukin-10 is inversely correlated with distant metastasis of renal cell carcinoma. Int. 1. Oncol (2002) 20:729–733.
   Google Scholar
• WANG M, HU Y, STEARNS ME: A novel IL-10 signalling mechanism regulates TIMP-1 expression in human prostate tumour cells. Br. 1 Cancer (2003) 88:1605–1614.
   PubMed Web of Science ®Google Scholar
• STEARNS ME, WANG M, HU Y, GARCIA FU, RHIM J: Interleuldn-10 blocks matrix metalloproteinase-2 and membrane Type 1-matrix metalloproteinase synthesis in primary human prostate tumor lines. Clin. Cancer Res. (2003) 9:1191–1199.
   PubMed Web of Science ®Google Scholar
• CERVENAK L, MORBIDELLI L, DONATI D et al: Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin- 10 . Blood (2000) 96:2568–2573.
   PubMed Web of Science ®Google Scholar
• KOHNO T, MIZUKAMIM H, SUZUKI M et al: Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. Cancer Res. (2003) 63:5091–5094.
   PubMed Web of Science ®Google Scholar
• NAGATA J, KIJIMA H, HATANAKA H et al: Correlation between interleukin-10 and vascular endothelial growth factor expression in human oesophageal cancer. Int. J. Ma Med. (2002) 10:169–172.
   PubMed Web of Science ®Google Scholar
• MOORE KW, VIEIRA P, FIORENTINO DF et al: Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science (1990) 248:1230–1234.
   PubMed Web of Science ®Google Scholar
• DINGY, QIN L, KOTENKO SV, PESTKA S, BROMBERG JS: A single amino acid determines the immunostimulatory activity of interleukin 10.1. Exp. Med. (2000) 191:213–224.
   Google Scholar
• HAIG DM, THOMSON J, MCINNES CJ et al.: A comparison of the anti-inflammatory and immuno-stimulatory activities of orf virus and ovine interleukin-10. Virus Res. (2002) 90:303–316.
   PubMed Web of Science ®Google Scholar
• MULLER A, RAFTERY M, SCHONRICH G: T cell stimulation upon long-term secretion of viral IL-10. Eur. Inimunol. (1999) 29:2740–2747.
   PubMed Web of Science ®Google Scholar
• LECHMAN ER, JAFFURS D, GHIVIZZANI SC et al: Direct adenoviral gene transfer of viral IL-10 to rabbit knees with experimental arthritis ameliorates disease in both injected and contralateral control knees. J. brununol. (1999) 163:2202–2208.
   Google Scholar
• MINTER RM, FERRY MA, MURDAY ME et al.: Adenoviral delivery of human and viral IL-10 in murine sepsis. Innnunol. (2001) 167:1053–1059.
   Google Scholar
• MINTER RM, FERRY MA, RECTENWALD JE et al.: Extended lung expression and increased tissue localisation of viral IL-10 with adenoviral gene therapy. Proc. Natl. Acad. Sci. USA (2001) 98:277–282.
   PubMed Web of Science ®Google Scholar
• HENKE PK, DEBRUNYE LA, STRIETER RIVI et al.: Viral IL-10 gene transfer decreases inflammation and cell adhesion molecule expression in a rat model of venous thrombosis. I Inimunol. (2002) 164:2131–2141.
   Google Scholar
• YANG Z, CHEN M, WU R et al: Suppression of autoimmune diabetes by viral IL-10 gene transfer. I brununol. (2002) 168:6479–6485.
   Google Scholar
• KAWAMOTO S, NITTA Y, TASHIRO F et al.: Suppression of TH1 cell activation and prevention of autoimmune diabetes in NOD mice by local expression of viral IL-10. Int. brununol. (2001) 13:685–694.
   Google Scholar
• •Expression of ebv1L-10 in pancreatic islets prevents autoimmune diabetes in NOD mice.
   Google Scholar
• BALASA B, DAVIES JD, LEE J et al: IL-10 impacts autoimmune diabetes via a CD8+ T cell pathway circumventing the requirement for CD4+ T and B lymphocytes. I Innnunol. (1998) 161:4420–4427.
   Google Scholar
• TAKAYAMA T, TAHARA H, THOMSON AW: Differential effects of myeloid dendritic cells retrovirally transduced to express mammalian or viral interleukin-10 on cytotoxic T lymphocyte and natural killer cell functions and resistance to tumor growth. Transplantation (2001) 71:1334–1340.
   PubMed Web of Science ®Google Scholar
• DEBRUYNE LA, LI K, CHAN SY et al: Lipid-mediated gene transfer of viral IL-10 prolongs vascularized cardiac allograft survival by inhibiting donor-specific cellular and humoral immune responses. Gene Ther. (1998) 5:1079–1087.
   PubMed Web of Science ®Google Scholar
• ZUO Z, WANG C, CARPENTER D et al.: Prolongation of allograft survival with viral IL-10 transfection in a highly histoincompatible model of rat heart allograft rejection. Transplantation (2001) 71:686–691.
   PubMed Web of Science ®Google Scholar
• QIN L, DING Y, TAHARA H, BROMBERG JS: Viral IL-10-induced immunosuppression requires TH2 cytokines and impairs APC function within the allograft. I Innnunol. (2001) 166:2385–2393.
   Google Scholar
• ADACHI O, YAMATO E, KAWAMOTO S et al.: High level expression of viral interleukin-10 in cardiac allografts fails to prolong graft survival. Transplantation (2002) 74: 1603-1608.
   Google Scholar
• •High level expression of ebvIL-10 in allografts exacerbate transplant rejection.
   Google Scholar
• DING W, BEISSERT S, DENG Let al.: Altered cutaneous immune parameters in transgenic mice overexpressing viral IL-10 in the epidermis. I. Clin. Invest. (2003) 111:1923–1931.
   Google Scholar
• SALEK-ARDAKANI S, STUART AD, ARRAND JE et al.: High level expression and purification of the Epstein-Barr virus encoded cytokine viral interleukin-10: efficient removal of endotoxin. Cytokine (2002) 17:1–13.
   PubMed Web of Science ®Google Scholar
• SALEK-ARDAKANI S, ARRAND JR, MACKETT M: Epstein-Barr virus encoded interleukin-10 inhibits HLA-Class I, ICAM-1, and B7 expression on human monocytes: implications for immune evasion by EBV. Virology (2002) 304:342–351.
   PubMed Web of Science ®Google Scholar
• TANNER JE, DIAZ-MITOMA F, ROONEY CM, ALFIERI C: Anti-interleukin-10 antibodies in patients with chronic active Epstein-Barr virus infection. J. Infect. Dis. (1997) 176:1454–1461.
   PubMed Web of Science ®Google Scholar
• SAULQUIN X, BODINIER M, PEYRAT MA et al.: Frequent recognition of BCRF1, a late lytic cycle protein of Epstein-Barr virus, in the HLA-B*2705 context: evidence for a TAP-independent processing. Eur. Innnunol. (2001) 31:708–715.
   PubMed Web of Science ®Google Scholar
• SAULQUIN X, SCOTET E, TRAUTMANN L et al.: +1 Frameshifting as a novel mechanism to generate a cryptic cytotoxic T lymphocyte epitope derived from human interleukin-10. I. Exp. Med. (2002) 195:353–358.
   PubMed Web of Science ®Google Scholar
• MAHOT S, SERGEANT A, DROUET E, GRUFFAT H: A novel function for the Epstein-Barr virus transcription factor EB1/ Zta: induction of transcription of the hIL-10 gene. J. Gen. Virol. (2003) 84:965–974.
   PubMed Web of Science ®Google Scholar
• KOTENKO SV, SACCANI S, IZOTOVA LS, MIROCHNITCHENKO OV, PESTKA S: Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL- 10) . Proc. Natl. Acad. Sci. USA (2000) 97:1695–1700.
   PubMed Web of Science ®Google Scholar
• LOCKRIDGE KM, ZHOU SS, KRAVITZ RH et al.: Primate cytomegaloviruses encode and express an IL-10-like protein. Virology (2000) 268:272–280.
   PubMed Web of Science ®Google Scholar
• JONES BC, LOGSDON NJ, JOSEPHSON K et al: Crystal structure of human cytomegalovirus IL-10 bound to soluble human IL-10R1. Proc. Natl. Acad Sci. USA (2002) 99:9404–9409.
   PubMed Web of Science ®Google Scholar
• •Structural analysis suggesting that cellular IL-10 and cmvIL-10 may induce strikingly different reorganisation of the IL-10R complex following binding to IL–10R1.
   Google Scholar
• SPENCER JV, LOCKRIDGE KM, BARRY PA et al: Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J. Viral. (2002) 76:1285–1292.
   PubMed Web of Science ®Google Scholar
• •Demonstrates that cmvIL-10 exerts in vitro irmnunosuppressive activities similar to those of cellular IL–10.
   Google Scholar
• FLEMING SB, HAIG DM, NETTLETON P et al.: Sequence and functional analysis of a homolog of interleukin-10 encoded by the parapoxvirus orf virus. Virus Genes (2000) 21:85–95.
   PubMed Web of Science ®Google Scholar
• IMLACH W, MCCAUGHAN CA, MERCER AA, HAIG D, FLEMING SB: Orf virus-encoded interleukin-10 stimulates the proliferation of murine mast cells and inhibits cytokine synthesis in murine peritoneal macrophages. J. Gen. Virol. (2002) 83:1049–1058.
   PubMed Web of Science ®Google Scholar
• LATEEF Z, FLEMING S, HALLIDAY G et al.: Orf virus-encoding interleulin-10 inhibits maturation, antigen presentation and migration of murine dendritic cells. J. Gen. Virol. (2003) 84:1101–1109.
   PubMed Web of Science ®Google Scholar